Shionogi, Nippon Kayaku Receive Approval for Cetrotide.Tokyo, Japan, Apr 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shionogi and Nippon Kayaku jointly announced on April 20 that they have received approval for Cetrotide, an agent for preventing premature ovulation ovulation /ovu·la·tion/ (ov?u-la´shun) the discharge of a secondary oocyte from a graafian follicle.ov´ulatory o·vu·la·tion n. The discharge of an ovum from the ovary. , from the Ministry of Health, Labor and Welfare. Cetrotide (cetrorelix acetate acetate (ăs`ĭtāt'), one of the most important forms of artificial cellulose-based fibers; the ester of acetic acid. The first patents for the production of fibers from cellulose acetate appeared at the beginning of the 20th cent. ), which was developed by German company Zentaris AG, is currently available in 92 countries worldwide. Nippon Kayaku will import the agent from Zentaris and manufacture it, while Shionogi will market the drug, which is scheduled to be available in September. Through the introduction of Cetrotide, the two companies aim to contribute to fertility fertility: see infertility. fertility Ability of an individual or couple to reproduce through normal sexual activity. About 80% of healthy, fertile women are able to conceive within one year if they have intercourse regularly without contraception. treatment in Japan. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion